%0 Journal Article
%T Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption.
%A Mdluli T
%A Slike BM
%A Curtis DJ
%A Shubin Z
%A Tran U
%A Li Y
%A Dussupt V
%A Mendez-Rivera L
%A Pinyakorn S
%A Stieh DJ
%A Tomaka FL
%A Schuitemaker H
%A Pau MG
%A Colby DJ
%A Kroon E
%A Sacdalan C
%A de Souza M
%A Phanupak N
%A Hsu DC
%A Ananworanich J
%A Ake JA
%A Trautmann L
%A Vasan S
%A Robb ML
%A Krebs SJ
%A Paquin-Proulx D
%A Rolland M
%J Cell Rep
%V 43
%N 6
%D 2024 Jun 25
%M 38850529
暂无%R 10.1016/j.celrep.2024.114344
%X A heterologous Ad26/MVA vaccine was given prior to an analytic treatment interruption (ATI) in people living with HIV-1 (mainly CRF01_AE) who initiated antiretroviral treatment (ART) during acute HIV-1. We investigate the impact of Ad26/MVA vaccination on antibody (Ab)-mediated immune responses and their effect on time to viral rebound. The vaccine mainly triggers vaccine-matched binding Abs while, upon viral rebound post ATI, infection-specific CRF01_AE binding Abs increase in all participants. Binding Abs are not associated with time to viral rebound. The Ad26/MVA mosaic vaccine profile consists of correlated non-CRF01_AE binding Ab and Fc effector features, with strong Ab-dependent cellular phagocytosis (ADCP) responses. CRF01_AE-specific ADCP responses (measured either prior to or post ATI) are significantly higher in individuals with delayed viral rebound. Our results suggest that vaccines eliciting cross-reactive responses with circulating viruses in a target population could be beneficial and that ADCP responses may play a role in viral control post treatment interruption.